Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study

Introduction: Pancreatic cancer is a devastating disease with an exceptionally poor prognosis. Complete resection of the primary tumour followed by adjuvant chemotherapy is the current standard treatment for patients with resectable disease and the only curative treatment option. However, long-term...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Roth, Susanne (VerfasserIn) , Springfeld, Christoph (VerfasserIn) , Diener, Markus K. (VerfasserIn) , Tjaden, Christin (VerfasserIn) , Knebel, Phillip (VerfasserIn) , Klaiber, Ulla (VerfasserIn) , Michalski, Christoph (VerfasserIn) , Mieth, Markus (VerfasserIn) , Jäger, Dirk (VerfasserIn) , Büchler, Markus W. (VerfasserIn) , Hackert, Thilo (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: August 20, 2019
In: BMJ open
Year: 2019, Jahrgang: 9, Heft: 8
ISSN:2044-6055
DOI:10.1136/bmjopen-2018-028696
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1136/bmjopen-2018-028696
Verlag, kostenfrei, Volltext: https://bmjopen.bmj.com/content/9/8/e028696
Volltext
Verfasserangaben:Susanne Roth, Christoph Springfeld, Markus K. Diener, Christine Tjaden, Phillip Knebel, Ulla Klaiber, Christoph W. Michalski, Markus Mieth, Dirk Jäger, Markus W. Büchler, Thilo Hackert

MARC

LEADER 00000caa a2200000 c 4500
001 1691164186
003 DE-627
005 20230428055009.0
007 cr uuu---uuuuu
008 200227s2019 xx |||||o 00| ||eng c
024 7 |a 10.1136/bmjopen-2018-028696  |2 doi 
035 |a (DE-627)1691164186 
035 |a (DE-599)KXP1691164186 
035 |a (OCoLC)1264295763 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Roth, Susanne  |d 1981-  |e VerfasserIn  |0 (DE-588)14180663X  |0 (DE-627)631813896  |0 (DE-576)32601764X  |4 aut 
245 1 0 |a Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer  |b the combiCaRe study  |c Susanne Roth, Christoph Springfeld, Markus K. Diener, Christine Tjaden, Phillip Knebel, Ulla Klaiber, Christoph W. Michalski, Markus Mieth, Dirk Jäger, Markus W. Büchler, Thilo Hackert 
264 1 |c August 20, 2019 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 27.02.2020 
520 |a Introduction: Pancreatic cancer is a devastating disease with an exceptionally poor prognosis. Complete resection of the primary tumour followed by adjuvant chemotherapy is the current standard treatment for patients with resectable disease and the only curative treatment option. However, long-term survival remains rare. Tumour cell dissemination due to manipulation during surgery may increase the rate of future metastases and local recurrence, and perioperative chemotherapy might diminish local, distant and circulating minimal residual disease. Yet, safety and feasibility of systemic chemotherapeutic treatments during pancreatic cancer resection have to be evaluated in a first instance. - Methods and analysis: This is a prospective, single-centre phase I/II feasibility study to investigate the safety and tolerability of a combination of intraoperative chemotherapy and surgical resection in pancreatic cancer. Forty patients with locally confined or borderline resectable pancreatic cancer, meeting all proposed criteria will be included. Participants will receive 400 mg/m2 calcium folinate over 2 hours and 2000 mg/m2 5-fluorouracil over 48 hours, started on the day before pancreatic surgery and thus continuing during surgery. Participants will be followed until 60 days after surgery. The primary endpoint is the 30-day overall complication rate according to the Clavien-Dindo classification. Secondary endpoints comprise toxicity and treatment associated complications. Patients receiving perioperative chemotherapy will be compared with a propensity score matched contemporary control group of 70 patients with pancreatic cancer receiving the standard treatment. This trial also contains an ancillary translational study to analyse disseminated tumour cells and effects of pharmacological interventions in pancreatic cancer. - Ethics and dissemination: CombiCaRe has been approved by the German Federal Institute for Drugs and Medical Devices (reference number 4042787) and the Medical Ethics Committee of Heidelberg University (reference number AFmo-269/2018). The results of this trial will be presented at national and international conferences and published in peer-reviewed journals. - Trial registration number: German Clinical Trials Register (DRKS00015766). 
650 4 |a gastroenterology 
650 4 |a gastrointestinal tumours 
650 4 |a pancreatic disease 
650 4 |a pancreatic surgery 
700 1 |a Springfeld, Christoph  |d 1972-  |e VerfasserIn  |0 (DE-588)123388910  |0 (DE-627)706281039  |0 (DE-576)293689385  |4 aut 
700 1 |a Diener, Markus K.  |d 1976-  |e VerfasserIn  |0 (DE-588)130896454  |0 (DE-627)507578562  |0 (DE-576)298401916  |4 aut 
700 1 |a Tjaden, Christin  |e VerfasserIn  |0 (DE-588)103328145X  |0 (DE-627)74081219X  |0 (DE-576)380859521  |4 aut 
700 1 |a Knebel, Phillip  |d 1977-  |e VerfasserIn  |0 (DE-588)131961829  |0 (DE-627)516320114  |0 (DE-576)298863170  |4 aut 
700 1 |a Klaiber, Ulla  |d 1985-  |e VerfasserIn  |0 (DE-588)1045771155  |0 (DE-627)775079944  |0 (DE-576)399230939  |4 aut 
700 1 |a Michalski, Christoph  |d 1977-  |e VerfasserIn  |0 (DE-588)129922250  |0 (DE-627)483655848  |0 (DE-576)297904302  |4 aut 
700 1 |a Mieth, Markus  |e VerfasserIn  |0 (DE-588)1071362240  |0 (DE-627)825726573  |0 (DE-576)433041072  |4 aut 
700 1 |a Jäger, Dirk  |d 1964-  |e VerfasserIn  |0 (DE-588)1032507535  |0 (DE-627)738505323  |0 (DE-576)380074125  |4 aut 
700 1 |a Büchler, Markus W.  |d 1955-  |e VerfasserIn  |0 (DE-588)120893339  |0 (DE-627)080952526  |0 (DE-576)292434146  |4 aut 
700 1 |a Hackert, Thilo  |d 1971-  |e VerfasserIn  |0 (DE-588)122158512  |0 (DE-627)70579346X  |0 (DE-576)182659208  |4 aut 
773 0 8 |i Enthalten in  |t BMJ open  |d London : BMJ Publishing Group, 2011  |g 9(2019,8) Artikel-Nummer e028696, 8 Seiten  |h Online-Ressource  |w (DE-627)654747075  |w (DE-600)2599832-8  |w (DE-576)339269340  |x 2044-6055  |7 nnas  |a Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer the combiCaRe study 
773 1 8 |g volume:9  |g year:2019  |g number:8  |g extent:8  |a Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer the combiCaRe study 
856 4 0 |u https://doi.org/10.1136/bmjopen-2018-028696  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://bmjopen.bmj.com/content/9/8/e028696  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20200227 
993 |a Article 
994 |a 2019 
998 |g 122158512  |a Hackert, Thilo  |m 122158512:Hackert, Thilo  |d 910000  |d 910200  |e 910000PH122158512  |e 910200PH122158512  |k 0/910000/  |k 1/910000/910200/  |p 11  |y j 
998 |g 120893339  |a Büchler, Markus W.  |m 120893339:Büchler, Markus W.  |d 910000  |d 910200  |e 910000PB120893339  |e 910200PB120893339  |k 0/910000/  |k 1/910000/910200/  |p 10 
998 |g 1032507535  |a Jäger, Dirk  |m 1032507535:Jäger, Dirk  |d 910000  |e 910000PJ1032507535  |k 0/910000/  |p 9 
998 |g 1071362240  |a Mieth, Markus  |m 1071362240:Mieth, Markus  |d 910000  |d 910200  |e 910000PM1071362240  |e 910200PM1071362240  |k 0/910000/  |k 1/910000/910200/  |p 8 
998 |g 129922250  |a Michalski, Christoph  |m 129922250:Michalski, Christoph  |d 50000  |e 50000PM129922250  |k 0/50000/  |p 7 
998 |g 1045771155  |a Klaiber, Ulla  |m 1045771155:Klaiber, Ulla  |d 910000  |d 910200  |e 910000PK1045771155  |e 910200PK1045771155  |k 0/910000/  |k 1/910000/910200/  |p 6 
998 |g 131961829  |a Knebel, Phillip  |m 131961829:Knebel, Phillip  |d 910000  |d 910200  |e 910000PK131961829  |e 910200PK131961829  |k 0/910000/  |k 1/910000/910200/  |p 5 
998 |g 103328145X  |a Tjaden, Christin  |m 103328145X:Tjaden, Christin  |d 910000  |d 910200  |e 910000PT103328145X  |e 910200PT103328145X  |k 0/910000/  |k 1/910000/910200/  |p 4 
998 |g 130896454  |a Diener, Markus K.  |m 130896454:Diener, Markus K.  |d 910000  |d 910200  |e 910000PD130896454  |e 910200PD130896454  |k 0/910000/  |k 1/910000/910200/  |p 3 
998 |g 123388910  |a Springfeld, Christoph  |m 123388910:Springfeld, Christoph  |d 910000  |d 910100  |e 910000PS123388910  |e 910100PS123388910  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 14180663X  |a Roth, Susanne  |m 14180663X:Roth, Susanne  |d 910000  |d 910200  |e 910000PR14180663X  |e 910200PR14180663X  |k 0/910000/  |k 1/910000/910200/  |p 1  |x j 
999 |a KXP-PPN1691164186  |e 3598947658 
BIB |a Y 
SER |a journal 
JSO |a {"title":[{"subtitle":"the combiCaRe study","title_sort":"Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer","title":"Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer"}],"language":["eng"],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"August 20, 2019"}],"name":{"displayForm":["Susanne Roth, Christoph Springfeld, Markus K. Diener, Christine Tjaden, Phillip Knebel, Ulla Klaiber, Christoph W. Michalski, Markus Mieth, Dirk Jäger, Markus W. Büchler, Thilo Hackert"]},"recId":"1691164186","person":[{"role":"aut","display":"Roth, Susanne","given":"Susanne","family":"Roth"},{"display":"Springfeld, Christoph","given":"Christoph","family":"Springfeld","role":"aut"},{"display":"Diener, Markus K.","given":"Markus K.","family":"Diener","role":"aut"},{"given":"Christin","display":"Tjaden, Christin","family":"Tjaden","role":"aut"},{"role":"aut","given":"Phillip","display":"Knebel, Phillip","family":"Knebel"},{"given":"Ulla","display":"Klaiber, Ulla","family":"Klaiber","role":"aut"},{"display":"Michalski, Christoph","given":"Christoph","family":"Michalski","role":"aut"},{"display":"Mieth, Markus","given":"Markus","family":"Mieth","role":"aut"},{"display":"Jäger, Dirk","given":"Dirk","family":"Jäger","role":"aut"},{"given":"Markus W.","display":"Büchler, Markus W.","family":"Büchler","role":"aut"},{"display":"Hackert, Thilo","given":"Thilo","family":"Hackert","role":"aut"}],"note":["Gesehen am 27.02.2020"],"relHost":[{"pubHistory":["2011 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"654747075","disp":"Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer the combiCaRe studyBMJ open","language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2044-6055"],"zdb":["2599832-8"],"eki":["654747075"]},"part":{"volume":"9","text":"9(2019,8) Artikel-Nummer e028696, 8 Seiten","year":"2019","extent":"8","issue":"8"},"note":["Gesehen am 02.10.20"],"origin":[{"publisherPlace":"London","dateIssuedKey":"2011","dateIssuedDisp":"2011-","publisher":"BMJ Publishing Group"}],"title":[{"title":"BMJ open","title_sort":"BMJ open"}]}],"id":{"doi":["10.1136/bmjopen-2018-028696"],"eki":["1691164186"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"8 S."}]} 
SRT |a ROTHSUSANNPROTOCOLOF2020